Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04 - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-04071525 , version 1 (17-04-2023)

Identifiants

  • HAL Id : hal-04071525 , version 1

Citer

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, et al.. Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04. 2022 ASCO Annual Meeting I, Jun 2022, Chicago, United States. pp.8002-8002. ⟨hal-04071525⟩
14 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More